Let me set the scene. A parent walks into my office, sits down, and says, “Doc, Timmy had two cookies at the birthday party. Should we start him on a GLP-1?”
I want to be clear up front: I am not anti-medicine. I am not anti-science. I went to medical school specifically so I could prescribe things that help children. But somewhere between “eat a vegetable” and “here’s a weekly injectable peptide that rewires your gut-brain appetite axis,” we skipped a few chapters. So let’s talk about it — with the appropriate amount of sarcasm, and also the actual facts, because apparently that combination is now considered edgy content.
First, the actual rules (yes, there are some)
For anyone about to email me, no, semaglutide is not FDA-approved for six-year-olds who look at a donut wrong. Here’s what’s actually approved:
Wegovy (semaglutide) is FDA-approved for weight management in adolescents 12 and older with obesity — defined as a BMI at or above the 95th percentile for age and sex — and it’s supposed to come bundled with a “reduced-calorie diet and increased physical activity,” not instead of one (FDA label).
Saxenda (liraglutide) got the 12-and-up nod back in 2020, and in 2025 was extended down to children ages 6 to 11 — a genuinely new and, frankly, jarring frontier (Rethink Peptides).
The pivotal teen trial for Wegovy — the one that got it approved — had 201 kids in it, ran 68 weeks, and showed about a 16% reduction in BMI (HealthRx).
Nobody, and I mean nobody, has long-term safety data past that window. We are, charitably, “still watching.”
So yes, the American Academy of Pediatrics’ 2023 guideline does say clinicians can offer GLP-1s to adolescents 12+ with obesity — but as an adjunct to “health behavior and lifestyle treatment,” not a replacement for it (AAP guideline via CDC). Somewhere in the journey from “adjunct treatment for a rigorously defined subset of adolescents with obesity” to “group chat consensus that every kid should be on a weekly shot,” something got lost. I’d like to formally nominate “nuance” as the missing object.
The part where I remind everyone this is a forever drug
Here’s the detail that tends to get glossed over in the group chats and the targeted ads: these drugs generally only work while you’re taking them. Stop the semaglutide, and appetite regulation tends to snap back toward baseline. Which means the honest conversation with a family isn’t “let’s try a shot for the summer,” it’s “are we prepared for this to be a lifelong medication regimen, started in a body that hasn’t finished growing, for a condition that could — in a meaningful subset of cases — also respond to changing what’s in the pantry?” That’s a much less Instagrammable pitch, I realize.
To be fair to the medication: for kids with severe obesity and real metabolic complications, this can be genuinely life-changing, and I’ve referred appropriate patients for it without hesitation. The FDA didn’t approve this for fun. What I object to is the vibe-shift where a tool meant for a narrow, carefully monitored population gets treated as a lifestyle convenience for anyone whose child owns a Halloween pillowcase.
Meanwhile, over to “boring old me”
While the injectable frontier marches on, I am over here, in the year of our lord 2026, still recommending the following cutting-edge interventions:
Vegetables, served more than once, because kids need repeated exposure before they’ll eat something new. Groundbreaking, I know. Water instead of a juice box that contains what is functionally a soda with a marketing team. Playing outside — an ancient ritual once known as “going outside,” now rebranded as “unstructured physical activity” so it sounds sufficiently clinical. Family meals where a screen is not the fourth person at the table. Sleep. Turns out a chronically under-slept nine-year-old eats like a raccoon in a dumpster. Who knew.
None of this comes in an auto-injector pen. None of this has a co-pay card. None of this will trend on social media with a testimonial. But it is, in fact, backed by roughly a century of pediatric evidence, it doesn’t require a lifelong prescription, and it doesn’t come with a package insert listing nausea, vomiting, and gallbladder disease as possible side effects.
So what am I actually saying
I’m saying: your toddler is not a science experiment, your teenager is not a case study, and “everyone at school is doing it” was a bad argument when it was about cigarettes and it’s still a bad argument now. If your adolescent meets the actual, FDA-defined, guideline-supported criteria — severe obesity, weight-related complications, a doctor who has actually examined them and isn’t just vibing off a TikTok — then GLP-1 therapy is a legitimate conversation to have, with informed consent about the “possibly forever” part included. If your six-year-old just really likes goldfish crackers, might I interest you in the wildly under-marketed intervention of fewer goldfish crackers?
Teach the eating habits. Save the injectable pharmacology for the kids who, per actual clinical guidelines, actually need it. And please, for the love of pediatric medicine, stop asking me to start your toddler on anything that requires a needle and a REMS program before they’ve mastered a fork.
Disclaimer: this post is satire, not individualized medical advice. GLP-1 receptor agonists are legitimate, FDA-regulated medications for specific pediatric populations under physician supervision — talk to your own child’s doctor before making any treatment decisions.
Sources:
CDC MMWR: Prescriptions for Obesity Medications Among Adolescents
FDA Wegovy Prescribing Label (2025)
Rethink Peptides: GLP-1 Drugs for Teens
HealthRx: Wegovy Pediatric Safety
PIER Network: Pharmacological Management of Obesity in Children